Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study.

Markovic SN, Galli F, Suman VJ, Nevala WK, Paulsen AM, Hung JC, Gansen DN, Erickson LA, Marchetti P, Wiseman GA, Signore A.

Oncotarget. 2018 Jul 13;9(54):30268-30278. doi: 10.18632/oncotarget.25666. eCollection 2018 Jul 13.

2.

18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma.

Youland RS, Packard AT, Blanchard MJ, Arnett AL, Wiseman GA, Kottschade LA, Dronca RS, Markovic SN, Olivier KR, Park SS.

Adv Radiat Oncol. 2017 Feb 24;2(2):204-210. doi: 10.1016/j.adro.2017.02.003. eCollection 2017 Apr-Jun.

3.

Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.

Epperla N, Pham AQ, Burnette BL, Wiseman GA, Habermann TM, Macon WR, Ansell SM, Inwards DJ, Micallef IN, Johnston PB, Markovic SN, Porrata LF, Colgan JP, Ristow KM, Nowakowski GS, Witzig TE.

Br J Haematol. 2017 Aug;178(3):427-433. doi: 10.1111/bjh.14688. Epub 2017 May 3.

PMID:
28466487
4.

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, Shanafelt TD, Sinha S, Le-Rademacher J, Feldman AL, Habermann TM, Witzig TE, Wiseman GA, Lin Y, Asmus E, Nowakowski GS, Conte MJ, Bowen DA, Aitken CN, Van Dyke DL, Greipp PT, Liu X, Wu X, Zhang H, Secreto CR, Tian S, Braggio E, Wellik LE, Micallef I, Viswanatha DS, Yan H, Chanan-Khan AA, Kay NE, Dong H, Ansell SM.

Blood. 2017 Jun 29;129(26):3419-3427. doi: 10.1182/blood-2017-02-765685. Epub 2017 Apr 19.

5.

Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma - tissue remains the issue.

Pham AQ, Broski SM, Habermann TM, Jevremovic D, Wiseman GA, Feldman AL, Maurer MJ, Ristow KM, Witzig TE.

Leuk Lymphoma. 2017 Oct;58(10):2342-2348. doi: 10.1080/10428194.2017.1300891. Epub 2017 Mar 14.

PMID:
28290723
6.

The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvement.

Jackson AE, Smeltzer JP, Habermann TM, Jones JM, Burnette B, Ristow K, Wiseman GA, Macon WR, Nowakowski GS, Witzig TE.

Am J Hematol. 2014 Sep;89(9):865-7. doi: 10.1002/ajh.23760. Epub 2014 Jun 19.

7.

Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Conte MJ, Bowen DA, Wiseman GA, Rabe KG, Slager SL, Schwager SM, Call TG, Viswanatha DS, Zent CS.

Leuk Lymphoma. 2014 Sep;55(9):2079-84. doi: 10.3109/10428194.2013.869801. Epub 2014 Feb 17.

8.

Outcome prediction in heart failure with atrial fibrillation: relative role of left ventricular ejection fraction and neurohormonal measures.

Clements IP, Wiseman GA, Hodge DO, Jacobson AF.

J Nucl Cardiol. 2013 Oct;20(5):821-9. doi: 10.1007/s12350-013-9751-x. Epub 2013 Jul 9.

PMID:
23835902
9.

A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.

Witzig TE, Wiseman GA, Maurer MJ, Habermann TM, Micallef IN, Nowakowski GS, Ansell SM, Colgan JP, Inwards DJ, Porrata LF, Link BK, Zent CS, Johnston PB, Shanafelt TD, Allmer C, Asmann YW, Gupta M, Ballas ZK, Smith BJ, Weiner GJ.

Am J Hematol. 2013 Jul;88(7):589-93. doi: 10.1002/ajh.23460. Epub 2013 Jun 12.

10.

Progress in gene therapy for prostate cancer.

Ahmed KA, Davis BJ, Wilson TM, Wiseman GA, Federspiel MJ, Morris JC.

Front Oncol. 2012 Nov 19;2:172. doi: 10.3389/fonc.2012.00172. eCollection 2012.

11.

Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma.

Moreno-Luna LE, Yang JD, Sanchez W, Paz-Fumagalli R, Harnois DM, Mettler TA, Gansen DN, de Groen PC, Lazaridis KN, Narayanan Menon KV, Larusso NF, Alberts SR, Gores GJ, Fleming CJ, Slettedahl SW, Harmsen WS, Therneau TM, Wiseman GA, Andrews JC, Roberts LR.

Cardiovasc Intervent Radiol. 2013 Jun;36(3):714-23. doi: 10.1007/s00270-012-0481-2. Epub 2012 Oct 24.

12.

The predictive value of imaging studies in evaluating regional lymph node involvement in Merkel cell carcinoma.

Colgan MB, Tarantola TI, Weaver AL, Wiseman GA, Roenigk RK, Brewer JD, Otley CC.

J Am Acad Dermatol. 2012 Dec;67(6):1250-6. doi: 10.1016/j.jaad.2012.03.018. Epub 2012 Apr 30.

PMID:
22552001
13.

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.

Micallef IN, Maurer MJ, Wiseman GA, Nikcevich DA, Kurtin PJ, Cannon MW, Perez DG, Soori GS, Link BK, Habermann TM, Witzig TE.

Blood. 2011 Oct 13;118(15):4053-61. doi: 10.1182/blood-2011-02-336990. Epub 2011 Jun 14.

14.

Prognostic value of 18F-fluorodeoxyglucose-positron emission tomography in patients with differentiated thyroid carcinoma and circulating antithyroglobulin autoantibodies.

Bogsrud TV, Hay ID, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, Reading CC, Björo T, Lowe VJ.

Nucl Med Commun. 2011 Apr;32(4):245-51. doi: 10.1097/MNM.0b013e328343a742.

PMID:
21278616
15.

The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.

Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK; North American Neuroendocrine Tumor Society (NANETS).

Pancreas. 2010 Aug;39(6):799-800. doi: 10.1097/MPA.0b013e3181ebb56f.

16.

The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum.

Anthony LB, Strosberg JR, Klimstra DS, Maples WJ, O'Dorisio TM, Warner RR, Wiseman GA, Benson AB 3rd, Pommier RF; North American Neuroendocrine Tumor Society (NANETS).

Pancreas. 2010 Aug;39(6):767-74. doi: 10.1097/MPA.0b013e3181ec1261.

PMID:
20664474
17.

NANETS consensus guidelines for the diagnosis of neuroendocrine tumor.

Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, Coppola D, Go VL; North American Neuroendocrine Tumor Society (NANETS).

Pancreas. 2010 Aug;39(6):713-34. doi: 10.1097/MPA.0b013e3181ebaffd. No abstract available.

PMID:
20664471
18.

A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.

Dispenzieri A, Wiseman GA, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, Laumann KM, Allred J, Geyer SM, Litzow MR, Gastineau DA, Inwards DJ, Micallef IN, Ansell SM, Porrata L, Elliott MA, Johnston PB, Hogan WJ, Gertz MA.

Am J Hematol. 2010 Jun;85(6):409-13. doi: 10.1002/ajh.21696.

19.

Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.

Shen S, Forero A, Meredith RF, Shah JJ, Knox SJ, Wiseman GA, Usrey ME, Lobuglio AF.

J Nucl Med. 2010 Jan;51(1):150-7. doi: 10.2967/jnumed.109.066597. Epub 2009 Dec 15.

20.

The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma.

Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, Reading CC, Björo T, Hay ID, Lowe VJ.

Mol Imaging Biol. 2010 Oct;12(5):547-53. doi: 10.1007/s11307-009-0276-2. Epub 2009 Dec 1.

PMID:
19949985
21.

Liver transplantation after radioembolization in a patient with unresectable HCC.

Luna LE, Kwo PY, Roberts LR, Mettler TA, Gansen DN, Andrews JC, Wiseman GA, Misra VL.

Nat Rev Gastroenterol Hepatol. 2009 Nov;6(11):679-83. doi: 10.1038/nrgastro.2009.165. Review.

22.

Hepatic vein tumor thrombus as a risk factor for excessive pulmonary deposition of microspheres during TheraSphere therapy for unresectable hepatocellular carcinoma.

Fleming CJ, Andrews JC, Wiseman GA, Gansen DN, Roberts LR.

J Vasc Interv Radiol. 2009 Nov;20(11):1460-3. doi: 10.1016/j.jvir.2009.07.033.

PMID:
19875064
23.

18F-FDG PET and PET/CT in Burkitt's lymphoma.

Karantanis D, Durski JM, Lowe VJ, Nathan MA, Mullan BP, Georgiou E, Johnston PB, Wiseman GA.

Eur J Radiol. 2010 Jul;75(1):e68-73. doi: 10.1016/j.ejrad.2009.07.035. Epub 2009 Aug 27.

PMID:
19716248
24.

Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial.

Wiseman GA, Pacak K, O'Dorisio MS, Neumann DR, Waxman AD, Mankoff DA, Heiba SI, Serafini AN, Tumeh SS, Khutoryansky N, Jacobson AF.

J Nucl Med. 2009 Sep;50(9):1448-54. doi: 10.2967/jnumed.108.058701. Epub 2009 Aug 18.

25.

Metastatic malignant melanoma.

Markovic SN, Erickson LA, Flotte TJ, Kottschade LA, McWilliams RR, Jakub JW, Farley DR, Tran NV, Schild SE, Olivier KR, Vuk-Pavlovic S, Sekulic A, Weenig RH, Pulido JS, Quevedo JF, Vile RG, Wiseman GA, Stoian I, Pittelkow MR; Melanoma Study Group of the Mayo Clinic Cancer Center.

G Ital Dermatol Venereol. 2009 Feb;144(1):1-26. Review.

PMID:
19218908
26.

Measuring granulocyte and monocyte accumulation at malignant lymphoma sites.

Juweid ME, Weiner GJ, Link BK, Horning SJ, Wiseman GA.

J Clin Oncol. 2009 Jan 1;27(1):154-5. doi: 10.1200/JCO.2008.19.2393. Epub 2008 Nov 24. No abstract available.

PMID:
19029411
27.

18F-FDG PET in the management of patients with anaplastic thyroid carcinoma.

Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, Reading CC, Hay ID, Lowe VJ.

Thyroid. 2008 Jul;18(7):713-9. doi: 10.1089/thy.2007.0350.

PMID:
18630999
28.

The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma.

Karantanis D, Subramaniam RM, Peller PJ, Lowe VJ, Durski JM, Collins DA, Georgiou E, Ansell SM, Wiseman GA.

Clin Lymphoma Myeloma. 2008 Apr;8(2):94-9. doi: 10.3816/CLM.2008.n.010.

PMID:
18501102
29.

Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma.

Johnston PB, Wiseman GA, Micallef IN.

Bone Marrow Transplant. 2008 Jun;41(11):919-25. doi: 10.1038/bmt.2008.82. Epub 2008 Apr 7. Review.

PMID:
18391991
30.

Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Wiseman GA, Conti PS, Vo K, Schilder RJ, Gordon LI, Emmanouilides C, Silverman DH, Witzig TE, Darif M, Molina A.

Clin Lymphoma Myeloma. 2007 Sep;7(8):514-7.

PMID:
18021468
31.

Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma.

Emmanouilides C, Witzig TE, Wiseman GA, Gordon LI, Wang H, Schilder R, Saville MW, Flinn I, Molina A.

Cancer Biother Radiopharm. 2007 Oct;22(5):684-91.

PMID:
17979571
32.

18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients.

Karantanis D, O'eill BP, Subramaniam RM, Witte RJ, Mullan BP, Nathan MA, Lowe VJ, Peller PJ, Wiseman GA.

Nucl Med Commun. 2007 Nov;28(11):834-41.

PMID:
17901765
33.

Focal F-18 fluoro-deoxy-glucose accumulation in the lung parenchyma in the absence of CT abnormality in PET/CT.

Karantanis D, Subramaniam RM, Mullan BP, Peller PJ, Wiseman GA.

J Comput Assist Tomogr. 2007 Sep-Oct;31(5):800-5.

PMID:
17895795
34.

A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.

Davis ID, Wiseman GA, Lee FT, Gansen DN, Hopkins W, Papenfuss AT, Liu Z, Moynihan TJ, Croghan GA, Adjei AA, Hoffman EW, Ingle JN, Old LJ, Scott AM.

Cancer Immun. 2007 Aug 17;7:13.

35.

Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland.

Karantanis D, Bogsrud TV, Wiseman GA, Mullan BP, Subramaniam RM, Nathan MA, Peller PJ, Bahn RS, Lowe VJ.

J Nucl Med. 2007 Jun;48(6):896-901. Epub 2007 May 15.

36.

The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT.

Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Collins DA, Kasperbauer JL, Strome SE, Reading CC, Hay ID, Lowe VJ.

Nucl Med Commun. 2007 May;28(5):373-81.

PMID:
17414887
37.

Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma.

Karantanis D, O'Neill BP, Subramaniam RM, Peller PJ, Witte RJ, Mullan BP, Wiseman GA.

Clin Nucl Med. 2007 Apr;32(4):271-4.

PMID:
17413571
38.

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.

Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, Darif M, Macklis R, Vo K, Wiseman GA.

Cancer. 2007 May 1;109(9):1804-10.

39.

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD; Imaging Subcommittee of International Harmonization Project in Lymphoma.

J Clin Oncol. 2007 Feb 10;25(5):571-8. Epub 2007 Jan 22.

PMID:
17242397
40.

Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia.

Rodriguez V, Anderson PM, Litzow MR, Erlandson L, Trotz BA, Arndt CA, Khan SP, Wiseman GA.

Leuk Lymphoma. 2006 Aug;47(8):1583-92.

PMID:
16966270
41.
42.

Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.

Emmanouilides C, Witzig TE, Gordon LI, Vo K, Wiseman GA, Flinn IW, Darif M, Schilder RJ, Molina A.

Leuk Lymphoma. 2006 Apr;47(4):629-36.

PMID:
16690521
43.

Sensitivity and utility of parathyroid scintigraphy in patients with primary versus secondary and tertiary hyperparathyroidism.

Pham TH, Sterioff S, Mullan BP, Wiseman GA, Sebo TJ, Grant CS.

World J Surg. 2006 Mar;30(3):327-32.

PMID:
16470331
44.

Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma.

Anderson PM, Wiseman GA, Erlandson L, Rodriguez V, Trotz B, Dubansky SA, Albritton K.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6895-900.

46.

Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.

Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, Mottaghy FM, Rohren EM, Blumstein NM, Stolpen A, Link BK, Reske SN, Graham MM, Cheson BD.

J Clin Oncol. 2005 Jul 20;23(21):4652-61. Epub 2005 Apr 18.

PMID:
15837965
47.

Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia.

Rodriguez V, Erlandson L, Arndt CA, Wiseman GA, Anderson PM.

Pediatr Transplant. 2005 Feb;9(1):122-6.

PMID:
15667625
48.

A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.

Dispenzieri A, Wiseman GA, Lacy MQ, Litzow MR, Anderson PM, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata L, Elliott MA, Lust JA, Greipp PR, Rajkumar SV, Fonseca R, Witzig TE, Erlichman C, Sloan JA, Gertz MA.

Leukemia. 2005 Jan;19(1):118-25.

PMID:
15526021
49.

Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy.

Wiseman GA, Leigh BR, Dunn WL, Stabin MG, White CA.

Cancer Biother Radiopharm. 2003 Apr;18(2):253-8.

PMID:
12804052
50.

Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.

Wiseman GA, Leigh BR, Erwin WD, Sparks RB, Podoloff DA, Schilder RJ, Bartlett NL, Spies SM, Grillo-López AJ, Witzig TE, White CA.

Cancer Biother Radiopharm. 2003 Apr;18(2):165-78.

PMID:
12804042

Supplemental Content

Loading ...
Support Center